Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Ala M. Alak"'
Publikováno v:
The Journal of Clinical Pharmacology. 41:628-635
Tacrolimus (FK506, Prograf), marketed for the prophylaxis of organ rejection following allogenic liver or kidney transplantation, is virtually completely metabolized. The major metabolic pathways are P450 3A4-mediated hydroxylation and demethylation.
Autor:
Ala M. Alak, Adali Niggebiugge, Melissa G. Cook, Anthony Chilton, Selina Moy, Paula Lizak, Shantil Menard
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 16:7-13
An HPLC/MS/MS assay for tacrolimus in whole blood using FR900520 as an internal standard was validated over the standard curve range of 0.100-10.040 ng ml-1. The calibration curve for tacrolimus in human blood gave a slope of 0.2481, an intercept of
Autor:
Ala M. Alak, Dawna Dressler, Jean W. Lee, Richard L. Sukovaty, Raymond H. Farmen, Ihor Bekersky
Publikováno v:
Therapeutic Drug Monitoring. 19:201-207
Tacrolimus (FK506) is a macrolide immunosuppressant approved for the prophylaxis of organ rejection in liver transplant. Immunoassays of low intra- and interday variability and high sensitivity are necessary to adequately characterize terminal elimin
Publikováno v:
Therapeutic Drug Monitoring. 19:88-91
A highly sensitive enzyme-linked immunosorbent assay method has been developed for the determination of tacrolimus in human blood samples. The assay is a modification of the previously published assay with improved sensitivity. Following extraction o
Publikováno v:
Therapeutic Drug Monitoring. 18:604-609
A sensitive and selective high-performance liquid chromatographic (HPLC) method has been developed for the determination of amphotericin B in human serum. After methanol deproteinization, amphotericin B and 3-nitrophenol (internal standard) are separ
Autor:
Ala M. Alak, Yuji Tokunaga
Publikováno v:
Pharmaceutical Research. 13:137-140
Purpose. To determine the concentrations of FK506 and its metabolites in blood from liver transplant patients and subjects with hepatic dysfunction.
Autor:
Ihor Bekersky, John Barret, Vijay Yeldandi, Stephen J. Chanock, Alison G. Freifeld, Nita Seibel, Maureen McEvoy, Ala M. Alak, Wyndham H. Wilson, Corina E. Gonzalez, Garry Boswell, Thomas J. Walsh, Donald N. Buell, Paul Jarosinski, Patricia Whitcomb
Publikováno v:
Antimicrobial agents and chemotherapy. 42(9)
The safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) administered for empirical antifungal therapy were evaluated for 36 persistently febrile neutropenic adults receiving cancer chemoth
Autor:
Ala M. Alak
Publikováno v:
Therapeutic drug monitoring. 19(3)
Tacrolimus (FK506, Prograf) is a macrolide immunosuppressant used for the prevention of organ rejection after transplantation. Tacrolimus demonstrates considerable interindividual variation in its pharmacokinetic profile. This has caused difficulty i
Publikováno v:
Journal of pharmaceutical and biomedical analysis. 15(3)
The objective of this study was to investigate the in-vitro metabolism of tacrolimus in liver slices from rats and humans. [14C]Tacrolimus (2 or 20 microM) was incubated with precision-cut human and rat liver slices in 12-well plates for up to 12 h.
Autor:
Ala M. Alak, Paula Lizak
Publikováno v:
Therapeutic drug monitoring. 18(3)
A Quality Assurance Program for the IMx assay for FK506 in whole blood samples was established to monitor the performance of the assay in clinical sites enrolled by Fujisawa USA, Inc. Forty investigative sites participating in the program were requir